Skip to main content
Premium Trial:

Request an Annual Quote

MolecularMD Lands NY State Approval for Notch 1 Mutation Test

NEW YORK (GenomeWeb) – MolecularMD today announced it has received approval from the New York State Department of Health for its Notch 1 gene mutation test.

The next-generation sequencing-based test is intended to support clinical trial enrollment, the firm said in a statement, and uses FFPE tissue and whole blood samples. The test has a five-day turnaround time.

Notch 1 mutations have been linked to cancers such as chronic lymphocytic leukemia and mantle cell lymphoma and put patients at greater risk for poor outcomes and reduced overall survival.

"Targeted therapy programs need accurate results quickly in a manner that allows their principal investigators to get their drug to patients while delivering upon regulatory requirements for drug-diagnostic approvals," MolecularMD CEO Dan Snyder said in a statement.

Portland, Oregon-based MolecularMD develops companion diagnostic testing for cancer treatments.

In March, the firm received ISO 13485:2003 Certification.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.